Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2

Fig. 3

a HCT116 spheroid growth over time after treatment with 30 kBq and 100 kBq 177Lu-AbN44v6 and 100 kBq 177Lu-rituximab as well as representative images of treated spheroids. b HCT116 spheroid growth over time after treatment with 20 μM of PM2 and the combination of 20 μM PM2 with 30 kBq and 100 kBq 177Lu-AbN44v6 and 100 kBq 177Lu-rituximab as well as representative images of treated spheroids. n ≥ 4, error bars presented as 95% confidence intervals. A combination of 20 μM PM2 with 30 kBq 177Lu-AbN44v6 differed significantly from monotherapies (p < 0.01 and p < 0.05 for PM2 and TRNT, respectively). A combination of 20 μM PM2 with 100 kBq 177Lu-AbN44v6 differed significantly from monotherapies (p < 0.0001 and p < 0.05 for PM2 and TRNT, respectively) as well as from the combination of 20 μM PM2 with 177Lu-rituximab (p < 0.0001), as assessed with One-way ANOVA followed by Tukey’s multiple comparisons test

Back to article page